Rigel Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Rigel Pharmaceuticals Inc cash flow-to-debt ratio. Rigel Pharmaceuticals Inc (RIGL) has a Cash Flow-to-Debt Ratio of 0.32x as of June 2026, meaning its operating cash flow of $30.65 Million could theoretically repay 0% of its total liabilities ($95.42 Million) in one year. Check Rigel Pharmaceuticals Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Rigel Pharmaceuticals Inc (1999–2025)
Cash flow-to-debt ratio of Rigel Pharmaceuticals Inc from 1999 to 2025. Historical debt coverage capacity for Rigel Pharmaceuticals Inc across 27 annual periods. Check total reinvestment intensity of Rigel Pharmaceuticals Inc to assess the company's total reinvestment commitment from operating cash flow.
Rigel Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (1999–2025)
Rigel Pharmaceuticals Inc cash flow-to-debt ratio by year from 1999 to 2025. Year-by-year debt coverage analysis for Rigel Pharmaceuticals Inc. For the full cash flow conversion analysis, see how efficiently does Rigel Pharmaceuticals Inc generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.62x | $75.66 Million | $122.11 Million | ▲ +216.3% |
| 2024 | 0.20x | $31.47 Million | $160.69 Million | ▲ +597.5% |
| 2023 | -0.04x | $-5.74 Million | $145.87 Million | ▲ +92.1% |
| 2022 | -0.50x | $-73.76 Million | $147.90 Million | ▼ -1262.0% |
| 2021 | 0.04x | $5.88 Million | $136.95 Million | ▲ +106.3% |
| 2020 | -0.68x | $-52.19 Million | $76.35 Million | ▼ -54.4% |
| 2019 | -0.44x | $-41.51 Million | $93.75 Million | ▲ +78.0% |
| 2018 | -2.01x | $-58.83 Million | $29.23 Million | ▲ +52.1% |
| 2017 | -4.20x | $-77.56 Million | $18.46 Million | ▼ -27.9% |
| 2016 | -3.28x | $-75.89 Million | $23.11 Million | ▼ -466.2% |
| 2015 | -0.58x | $-23.41 Million | $40.37 Million | ▲ +78.5% |
| 2014 | -2.69x | $-69.75 Million | $25.89 Million | ▲ +44.3% |
| 2013 | -4.83x | $-86.06 Million | $17.81 Million | ▼ -18.8% |
| 2012 | -4.07x | $-85.19 Million | $20.95 Million | ▼ -22.9% |
| 2011 | -3.31x | $-69.38 Million | $20.96 Million | ▼ -245.6% |
| 2010 | 2.27x | $46.74 Million | $20.56 Million | ▲ +168.3% |
| 2009 | -3.33x | $-102.78 Million | $30.88 Million | ▼ -27.6% |
| 2008 | -2.61x | $-103.52 Million | $39.69 Million | ▼ -67.9% |
| 2007 | -1.55x | $-52.21 Million | $33.61 Million | ▼ -12.8% |
| 2006 | -1.38x | $-35.84 Million | $26.01 Million | ▼ -53.1% |
| 2005 | -0.90x | $-35.17 Million | $39.08 Million | ▲ +37.4% |
| 2004 | -1.44x | $-38.15 Million | $26.52 Million | ▲ +31.0% |
| 2003 | -2.09x | $-32.44 Million | $15.55 Million | ▼ -14.2% |
| 2002 | -1.83x | $-34.53 Million | $18.90 Million | ▼ -100.1% |
| 2001 | -0.91x | $-15.98 Million | $17.51 Million | ▼ -20.1% |
| 2000 | -0.76x | $-11.59 Million | $15.25 Million | ▼ -59.2% |
| 1999 | -0.48x | $-7.83 Million | $16.41 Million | — |